文献检索文档翻译深度研究

邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

不再提醒

Teclistamab impairs detection of BCMA CAR-T cells.

作者信息

Glatte Bettina, Wenk Kerstin, Grahnert Anja, Friedrich Maik, Merz Maximilian, Vucinic Vladan, Fischer Luise, Reiche Kristin, Alb Miriam, Hudecek Michael, Franz Paul, Fricke Stephan, Platzbecker Uwe, Koehl Ulrike, Sack Ulrich, Boldt Andreas, Hauschildt Sunna, Weiss Ronald

机构信息

Institute of Clinical Immunology, Medical Faculty, Leipzig University, Leipzig and University of Leipzig Medical Center, Leipzig, Germany.

Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.

出版信息

Blood Adv. 2023 Aug 8;7(15):3842-3845. doi: 10.1182/bloodadvances.2023009714.

DOI:10.1182/bloodadvances.2023009714

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10393749/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee18/10393749/7c8d20792929/BLOODA_ADV-2023-009714-gr1.jpg

相似文献

[1]

Teclistamab impairs detection of BCMA CAR-T cells.

Blood Adv. 2023-8-8

[2]

High antigen density of BCMA: friend or foe to CAR T cells?

J Immunother Cancer. 2022-9

[3]

CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Mol Ther. 2018-6-18

[4]

BCMA-CAR T-cell treatment-associated parkinsonism.

Blood. 2023-10-5

[5]

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Mol Ther. 2019-4-8

[6]

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.

Int J Mol Sci. 2022-1-14

[7]

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.

Hum Gene Ther. 2018-5

[8]

BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.

Cancer Lett. 2023-1-28

[9]

A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.

Cell Immunol. 2021-5

[10]

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.

Ann Hematol. 2019-1-28

引用本文的文献

[1]

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Blood Cancer Discov. 2025-1-8

[2]

Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment.

Biomedicines. 2024-7-24

本文引用的文献

[1]

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.

Front Immunol. 2022

[2]

Role of bridging therapy during chimeric antigen receptor T cell therapy.

EJHaem. 2021-11-19

[3]

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.

Int J Mol Sci. 2022-1-14

[4]

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.

J Exp Clin Cancer Res. 2022-1-3

[5]

The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond.

Cancers (Basel). 2021-9-19

[6]

Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.

Front Immunol. 2021-5-3

[7]

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

N Engl J Med. 2021-2-25

[8]

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.

Blood Adv. 2020-9-22

[9]

Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.

Clin Biochem. 2018-1

[10]

International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.

Transfusion. 2016-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

推荐工具

医学文档翻译智能文献检索